Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Cancer Research|January 20, 2004
The Cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of Cyclin D1, and activates the mitogen-activated protein kinase pathwaySteven R Whittaker, Mike I Walton, Michelle D Garrett, et al.
Progress in Cell Cycle Research|November 5, 2003
The contemporary drug development process: advances and challenges in preclinical and clinical developmentMichelle D Garrett, Mike I Walton, Edward McDonald, et al.
Molecular Cancer Therapeutics|September 20, 2005
An evaluation of the ability of pifithrin-alpha and -beta to inhibit p53 function in two wild-type p53 human tumor cell linesMike I Walton, Stuart C Wilson, Ian R Hardcastle, et al.
Current Opinion in Pharmacology|August 30, 2008
Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promisesTimothy A Yap, Michelle D Garrett, Mike I Walton, et al.
Journal of the National Cancer Institute|November 6, 2003
Magnetic resonance spectroscopic pharmacodynamic markers of the heat shock protein 90 inhibitor 17-allylamino,17-demethoxygeldanamycin (17AAG) in human colon cancer modelsYuen-Li Chung, Helen Troy, Udai Banerji, et al.
Molecular Cancer Therapeutics|April 29, 2010
AT7867 is a potent and oral inhibitor of AKT and p70 S6 kinase that induces pharmacodynamic changes and inhibits human tumor xenograft growthKyla M Grimshaw, Lisa-Jane K Hunter, Timothy A Yap, et al.
Molecular Cancer Therapeutics|December 31, 2010
Preclinical pharmacology, antitumor activity, and development of pharmacodynamic markers for the novel, potent AKT inhibitor CCT128930Timothy A Yap, Mike I Walton, Lisa-Jane K Hunter, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 30, 2012
CCT244747 is a novel potent and selective CHK1 inhibitor with oral efficacy alone and in combination with genotoxic anticancer drugsMike I Walton, Paul D Eve, Angela Hayes, et al.
Oncotarget|August 22, 2015
The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphomaMike I Walton, Paul D Eve, Angela Hayes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 12, 2012
AT13148 is a novel, oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activityTimothy A Yap, Mike I Walton, Kyla M Grimshaw, et al.
Pageof 1